Irina Rebin

Prix à l'honneur

JUVE Awards 2023

Law firm of the year for IP Law

Irina is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group. Her practice includes advising pharmaceutical, medical device, and biotechnology companies and investors on all regulatory matters throughout the entire life cycle of medicinal products, medical devices, and IVDs: from preclinical research and clinical trials, manufacturing, and market access to distribution (including post-market surveillance).

She also provides legal advice on genetic engineering, food (including food supplements), and cosmetics. Irina complements this practice focus by drafting and negotiating corresponding industry-specific agreements (including research and development agreements, license agreements, clinical trial agreements, contract/manufacturing and distribution agreements (including quality agreements)) and by advising on (cross-border) transactions in the healthcare sector.

CV

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

Carrière

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

Formation

2019 Second state examination, Munich

2014 – 2017 Doctoral studies at Ludwig Maximilians University Munich

2014 - 2015 Doctoral studies at Georg August University Göttingen

Publications

§§ 40-42e AMG in: Rehmann, AMG, 6. Aufl. [in Bearb./vor. Anfang 2026] § 15 Entwicklung des Arzneimittelprüfrechts

§ 16 Grundlagen klinischer Arzneimittelprüfungen

§ 17 Zentrale Voraussetzungen klinischer Prüfungen im Überblick in: Spickhoff/Handorn: Handbuch Medizinisches Forschungsrecht, C. H. Beck, München, 2023

§ 2 ProdHaftG im Beck-Online-Großkommentar (seit 2015)

Langues étrangères

Prix et distinctions

JUVE Awards 2023

Featured

Actualités et publications récentes

View Irina's insights

Cliquer ici pour en savoir plus

Sciences de la vie et Santé

The 2026 Pharma Package: A New Regulatory Framework for Medicinal Products in the EU

15 avril 2026

par Irina Rebin

International Life Sciences Newsletter - Life Sciences Legal Lens Vol 1

Impact of the new Biotech Act on Clinical Trials in the EU

A European Perspective #1 | EU Biotech Act: Faster Clinical Trial Approvals Ahead | The European Commission’s proposed Biotech Act aims to streamline clinical trial procedures, shorten approval timelines, and harmonise data protection rules across the EU. If adopted, the reform could significantly accelerate multinational clinical research in the EU.

15 avril 2026

Quick read

par Irina Rebin

4 de 9 Publications

Cliquer ici pour en savoir plus

International Life Sciences Newsletter - Life Sciences Legal Lens Vol 1

No claim for damages as a result of participation in clinical drug trials

A European Perspective #1 | GERMANY | The Frankfurt am Main Regional Court confirms: No reduction in the burden of proof (presumption of causality) pursuant to Section 84 (2) of the German Medicines Act (AMG) for IMP (not even by analogy) and no liability on the part of the sponsor in the event of (insufficient) risk information provided by the investigating physician.

1 avril 2026

par Irina Rebin

7 de 9 Publications

Cliquer ici pour en savoir plus

Irina Rebin

JUVE Awards 2023

Expertise

Services et Groupes

Secteurs

CV

Carrière

Formation

Publications

Langues étrangères

Prix et distinctions

JUVE Awards 2023

Actualités et publications récentes

The 2026 Pharma Package: A New Regulatory Framework for Medicinal Products in the EU

Irina Rebin

JUVE Awards 2023

Expertise

Services et Groupes

Secteurs

CV

Carrière

Formation

Publications

Langues étrangères

Prix et distinctions

JUVE Awards 2023

Actualités et publications récentes

The 2026 Pharma Package: A New Regulatory Framework for Medicinal Products in the EU

Related news & insights

European Franchise Newsletter n° 45

A Collision Course: Increased Potential for Conflict Due to the Regulation on the Security of Industrial and Supply Chains and the Regulation on Countering Unlawful Extraterritorial Jurisdiction by Foreign States of the People’s Republic of China

EU Anti-Money Laundering Regulation Effective July 2027: The New EU Single Rulebook

“Grant Compliance”: Lessons from COVID-19 Relief Funds

NIS2 – Cybersecurity as an Ongoing Responsibility

NIS2 is here – cybersecurity becomes a top priority

Competition for Talent – Caution regarding Non-Poaching and Non-Hiring Agreements!

Taylor Wessing advises the LEO III Fund on the acquisition of H.K.O Isolier- und Textiltechnik GmbH from Saint-Gobain

Taylor Wessing at the IBA Annual Conference: Let’s Connect in Copenhagen

Taylor Wessing strengthens its patent practice with the appointment of equity partner Dr Michael Schneider and salary partner Philipp Neels

Autres avocats qui pourraient vous intéresser

Rendez-vous à